Monoamine oxidase-inhibiting antidepressants. A clinical update.
This article outlines the latest information on the clinical efficacy of MAOIs and provides the physician with guidelines for their safe use. The important side effects of this class of drugs are also summarized along with an up-to-date account of their possible molecular mechanism of action.
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D004032:Diet; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009290:Narcolepsy / Q000188:drug therapy; D010624:Phenelzine / Q000627:therapeutic use; D014439:Tyramine / Q000009:adverse effects
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine; D014439:Tyramine